Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Nucana ( (NCNA) ) has shared an update.
On May 6, 2026, NuCana published its 2025 UK Annual Report for the year ended December 31, 2025 and sent it, along with the notice of its 2026 annual general meeting (AGM) and proxy materials, to its ordinary shareholders. Around the same date, Citibank, as depositary for NuCana’s American Depositary Shares, began mailing voting materials to ADS holders of record as of May 1, 2026 so they can instruct how their underlying shares should be voted at the AGM.
The AGM is scheduled for June 8, 2026 in Edinburgh, with resolutions covering director re‑elections, auditor re‑appointment and remuneration, approval of 2025 accounts and remuneration reports, and significant share capital restructuring via sub-division of ordinary and deferred shares. Shareholders are also being asked to renew authorities to allot shares and disapply pre-emption rights up to a £5 million nominal amount, and the board has warned that failure to pass these resolutions would severely compromise NuCana’s ability to finance its plans on a continuing basis.
Spark’s Take on NCNA Stock
According to Spark, TipRanks’ AI Analyst, NCNA is a Neutral.
The score is primarily held down by weak financial performance (pre-revenue losses and ongoing cash burn) and a negative P/E. Technicals are mixed—some near-term strength above the 20-day average, but negative MACD and price well below longer-term moving averages keep the overall score below average.
To see Spark’s full report on NCNA stock, click here.
More about Nucana
NuCana plc is a UK-based oncology-focused biopharmaceutical company developing cancer treatments, with its shares traded in the form of ordinary shares in the UK and American Depositary Shares in the U.S. The company operates within the global oncology drug development sector, where continued access to capital markets and shareholder support is critical to funding its research and clinical programs.
Average Trading Volume: 39,532
Technical Sentiment Signal: Sell
Current Market Cap: $9.2M
For an in-depth examination of NCNA stock, go to TipRanks’ Overview page.